BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ, Lam CS, Heerspink HL, Khunti K. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine 2021;32:100739. [PMID: 33688855 DOI: 10.1016/j.eclinm.2021.100739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Ther Adv Endocrinol Metab 2022;13:20420188221112490. [PMID: 35874312 DOI: 10.1177/20420188221112490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Prokopidis K, Isanejad M, Akpan A, Stefil M, Tajik B, Giannos P, Venturelli M, Sankaranarayanan R. Exercise and nutritional interventions on sarcopenia and frailty in heart failure: a narrative review of systematic reviews and meta-analyses. ESC Heart Fail 2022. [PMID: 35840310 DOI: 10.1002/ehf2.14052] [Reference Citation Analysis]
3 Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, Wang Y, Xu L. The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture. Front Endocrinol 2022;13:918350. [DOI: 10.3389/fendo.2022.918350] [Reference Citation Analysis]
4 Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes Obes Metab 2022. [PMID: 35676798 DOI: 10.1111/dom.14799] [Reference Citation Analysis]
5 Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2021:ehab777. [PMID: 35023547 DOI: 10.1093/eurheartj/ehab777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 36] [Article Influence: 1.0] [Reference Citation Analysis]
6 Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation 2021. [PMID: 34775784 DOI: 10.1161/CIRCULATIONAHA.121.057983] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
7 Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E; D&CVD EASD Study Group. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol 2021;20:218. [PMID: 34740359 DOI: 10.1186/s12933-021-01408-1] [Cited by in F6Publishing: 9] [Reference Citation Analysis]